Skip to main content
Chemomab Therapeutics Ltd. logo

Chemomab Therapeutics Ltd. — Investor Relations & Filings

Ticker · CMMB ISIN · US16385C1045 US Manufacturing
Open in API
Filings indexed 332 across all filing types
Latest filing 2019-05-28 Proxy Solicitation & In…
Country US United States of America
Listing US CMMB

About Chemomab Therapeutics Ltd.

https://www.chemomab.com/

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's scientific platform is based on the discovery of the soluble protein CCL24's central role in driving the cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class monoclonal antibody designed to neutralize CCL24, thereby interfering with the primary pathways that promote these conditions. Nebokitug has demonstrated disease-modifying potential in multiple clinical trials and has received Orphan Drug and Fast Track designations from the U.S. FDA for the treatment of primary sclerosing cholangitis (PSC). Following positive Phase 2 results, the company is preparing for a potential Phase 3 trial for nebokitug in PSC.

Recent filings

Filing Released Lang Actions
FORM 6-K
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Form 6-K filed by Anchiano Therapeutics Ltd. It announces the date and location of the 2019 Annual General Meeting (AGM) of shareholders and mentions that a proxy statement and proxy card will be distributed to shareholders. The document includes a notice of the meeting and proxy materials as exhibits. The text does not contain the actual AGM materials or presentations but rather announces the meeting and the forthcoming distribution of proxy materials. The document length is 2350 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Proxy Solicitation & Information Statement (PSI) since it relates to materials sent to shareholders to provide information and request votes for the AGM.
2019-05-28 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer pursuant to SEC rules. It announces the company's first quarter 2019 financial results and attaches a press release dated May 22, 2019. The document itself is short (1758 characters) and primarily serves to announce the release of financial results rather than containing detailed financial statements or analysis. According to the 'Menu vs Meal' rule, such a brief announcement with an attached press release is not the full financial report but an announcement of it. Therefore, this document should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-05-22 English
20-F/A
Annual Report FY 2018
2019-04-24 English
FORM 20-F
Annual Report FY 2018
2019-03-25 English
FORM 6-K
Delisting Announcement Classification · 100% confidence The document is a Form 6-K filed by Anchiano Therapeutics Ltd., which is a report of a foreign private issuer pursuant to SEC rules. The content focuses on the company's announcement regarding its intention to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange (TASE), including details about the delisting timeline and instructions for shareholders to convert shares to American Depositary Shares (ADSs). There is no financial data, earnings information, or detailed report content. The document is primarily an official announcement about a delisting event. According to the filing definitions, this fits the category of a Delisting Announcement (DLST). The document length is 3310 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is DLST with high confidence.
2019-03-14 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Anchiano Therapeutics Ltd., reporting the announcement of its fourth quarter and full year 2018 financial results via a press release attached as Exhibit 99.1. The document itself is short (1797 characters) and primarily serves to furnish the press release to the SEC. It does not contain the full financial report or detailed financial statements but references the press release. According to the 'Menu vs Meal' rule, such a document is an announcement of a report rather than the report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes Form 6-K filings that provide announcements or press releases without full financial data.
2019-03-12 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.